Weight loss drugs such as Wegovy, Zepbound and other GLP-1s have revolutionized the field of medical weight loss. Most of these drugs started their lives as diabetes medications. Since being approved for weight loss they have also been indicated for heart disease, and now new research seems to indicate they could be our very first “longevity drugs.”
There is emerging evidence that suggests a strong link between GLP-1 these medications and increased longevity, primarily by reducing risks associated with obesity, diabetes, and cardiovascular diseases.
A recent study published in the journal Nature Biotechnology, found that GLP-1s may improve healthspan by mitigating age-related conditions like neurodegeneration and chronic inflammation, though long-term human data specifically for longevity is still needed.
Key Takeaways From This Study:
- Reduced Disease Risk: GLP-1 drugs are heavily linked to reduced risks of heart attack, stroke, heart failure, and cardiovascular-related mortality.
- Metabolic Improvements: Beyond weight loss, they enhance insulin sensitivity and address metabolic dysfunction, which are key drivers of aging.
- Potential Healthspan Extension: Research indicates potential neuroprotective benefits, with some data suggesting a lower risk of cognitive decline and dementia.
- Scientific Opinion: While some researchers hypothesize that GLP-1s could act as “longevity drugs” due to their broad positive impact on age-related diseases, others argue that comprehensive, long-term human studies are needed to prove they extend lifespan directly, beyond treating obesity and diabetes.
You can read the complete study which was published in the journal Nature Biotechnology, by clicking on the link.